Stocks and Investing Stocks and Investing
Fri, August 5, 2022

Neena Bitritto-Garg Downgraded (ACAD) to Hold and Decreased Target to $15 on, Aug 5th, 2022


Published on 2024-10-27 22:28:36 - WOPRAI, Neena Bitritto-Garg
  Print publication without navigation


Neena Bitritto-Garg of Citigroup, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Decreased Target from $19 to $15 on, Aug 5th, 2022.

Neena has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 3 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $22 on, Friday, July 15th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022


These are the ratings of the 4 analyists that currently disagree with Neena


  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $27 on, Monday, July 11th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, June 21st, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022

Contributing Sources